In summary, there is a considerable number of clinical studies reporting the potential benefit of GLP-1RAs for use in cognitive disorders, including dementias and Parkinsons disease, although the majority are observational and can only suggest association
The evidence base for their use in weight management remains very limited, and their use falls outside the scope of standard NHS prescribing
pharmacovigilance experts are monitoring for adverse signals beyond clinical trials
Studies show that long-term use of recommended doses is safe and beneficial for metabolism, endurance, and heart health.
Preliminary findings from Virtas book of business indicate its prescribing solution drove transformative health outcomes and immediate business impact, including: Substantial reduction in GLP-1 utilization and corresponding costs Responsible Prescribing prevents ongoing GLP-1 use by over 50% among current GLP-1 users, lowering costs for payers

KLOW is a multi-compound peptide blend combining four well-researched compounds in a single lyophilized vial: BPC-157 studied for tendon, ligament, gut lining, and musculoskeletal tissue repair TB-500 (Thymosin Beta-4 fragment) studied for systemic tissue repair, angiogenesis, and anti-inflammatory effects GHK-Cu (Copper Peptide) studied for collagen and elastin synthesis, skin regeneration, and wound healing KPV a tripeptide fragment of alpha-MSH studied for anti-inflammatory and gut mucosal healing properties Together, these four compounds target complementary pathways in tissue repair, inflammation modulation, skin health, and cellular regeneration covering a broader research scope in a single vial than any of the individual components alone